Navigation Links
Gamma Knife Users Share Latest Advances for Treating Cancer, Other Brain Disorders at Society Meeting in Greece
Date:5/12/2010

ATLANTA and STOCKHOLM, May 12 /PRNewswire/ -- A record 332 oral and poster presentations comprise the scientific program for Elekta's 15th International Leksell Gamma Knife® Society Meeting, which convenes May 16-20 at the Athenaeum InterContinental Hotel (Athens, Greece). The most ever submitted in the society's 21-year history, the presentations also will be posted on the Elekta website after the meeting. Attendance at the conference is estimated at 500, including neurosurgeons, radiation oncologists and other medical specialists from around the world.

A major focus of the upcoming meeting will be presentations discussing how Elekta's fifth generation Leksell Gamma Knife® Perfexion™ system is benefiting radiosurgery practices.

"After two decades in clinical practice, Gamma Knife surgery continues to be the preferred method for minimally invasive treatment of many brain disorders, particularly metastases," says Dan Leksell, MD, son of Lars Leksell and Senior Advisor at Elekta. "Leksell Gamma Knife has evolved to provide increasingly greater degrees of precision and a more streamlined workflow. At the upcoming meeting, we will hear how Leksell Gamma Knife Perfexion is helping patients, and adding new indications through the Extend™ program that weren't possible to treat before this system's introduction."

Presentations to feature clinical and Workflow advantages of Perfexion and Extend program


'/>"/>
SOURCE Elekta
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
2. Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia
3. Elekta Announces Clinical Start-Up of New Leksell Gamma Knife(R) Perfexion(TM) at UPMC
4. Bertrand Study Finds Significant Value in Breast-Specific Gamma Imaging (BSGI) as an Adjunctive Procedure in Breast Diagnostics
5. FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
6. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
7. Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimers Disease Announced
8. Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
9. European Unions CHMP Issues Positive Opinion on Sugammadex
10. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
11. U.S. FDA Issues Action Letter for Sugammadex
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... SAN DIEGO , May 23, 2013 Neurocrine ... Kevin Gorman , President and Chief Executive ... Bank 38 th Annual dbAccess Health Care Conference in ... Thursday, May 30 at 11:20 a.m. Eastern Time / 8:20 ... be accessed on the Company,s website at http://www.neurocrine.com . ...
(Date:5/23/2013)... OAKS, Calif. , May 23, 2013 Amgen ... Bank 38 th Annual  Healthcare Conference on Thursday, May ... Boston , beginning at 9:20 a.m. Eastern Daylight Time. ... Relations at Amgen, will present at the conference. Live audio ... on Amgen,s website, www.amgen.com , under Investors. A replay ...
(Date:5/23/2013)... 2013  Haemonetics Corporation (NYSE: HAE ) announced ... EVP-Business Development, will present at The Deutsche Bank 38 th ... MA on May 29, 2013 at 1:30pm Eastern ... The public may access Mr. Lindop,s presentation live via ... Haemonetics (NYSE: HAE ) is a ...
Breaking Medicine Technology:
... THOUSAND OAKS, Calif. and NEW YORK, May 25, 2011 ... Inc. (NYSE: PFE ) today announced new ... body of evidence supporting the efficacy and safety profile ... the United States (U.S.). Eighteen abstracts across four indications, ...
... May 25, 2011 Boston Scientific Corporation (NYSE: ... U.S. Food and Drug Administration (FDA) to market its 2.25 ... in vessels as small as 2.25 mm in diameter.  The ... The PROMUS Stent features a thin-strut, open-cell design ...
Cached Medicine Technology:Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 2Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 3Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 4Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 5Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 6Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 7Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 8Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 9Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 10Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 11Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 12Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 13Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System 2Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System 3Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System 4
(Date:5/23/2013)... , , THURSDAY, May 23 (HealthDay News) -- Glucosamine supplements ... and knee osteoarthritis may have an unexpected side effect: ... new study of older adults suggests. Glaucoma ... (IOP) or pressure inside the eye. Left untreated, glaucoma ... In the new study of 17 people, ...
(Date:5/23/2013)... -- A modified version of the polio virus ... research suggests. Scientists at Duke Cancer Institute ... uses an engineered form of the virus that ... cells. The therapy shows promise in the treatment ... tumor, they said. "These early results are ...
(Date:5/23/2013)... (HealthDay News) -- People who eat at fast-food restaurants ... and teens are the worst offenders, a new study ... their meals by as much as 34 percent, parents ... and adults by as much as 20 percent," study ... release from the Robert Wood Johnson Foundation, which helped ...
(Date:5/23/2013)... Memorial Day Focus Spotlight on Military ... a part of the U.S. Military for more than ... it, these men and women will be honored for ... America. As veterans transition to civilian life, there ... workplace chaplaincy world. , Marketplace Chaplains, America’s original ...
(Date:5/23/2013)... (May 23, 2013)Don,t doubt it when a woman harried ... remembering things. A new study published online in ... Society (NAMS), helps confirm with objective tests that what ... In the past, some studies showed that hot flashes ... studies showed that, even though there was a relationship ...
Breaking Medicine News(10 mins):Health News:Glucosamine Supplements Tied to Risk of Eye Condition 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 3Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2Health News:How Many Calories in Your Fast-Food Meal? Guess Again 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 3
... May 26, 2010 Complete Genomics Inc., a third-generation ... a wholly owned member of the Roche Group (SIX: ... and analytics services to sequence and compare a patient,s ... like this allow researchers to compare the patient,s genome ...
... amounts in the gums, those tough pink tissues that hold the ... to develop an early, non-invasive test for gum disease, the No. ... quart of which people produce each day, but gingival crevicular fluid ... tooth. The study, the most comprehensive analysis of GCF to date, ...
... People undergoing bisphosphonate therapy to prevent or treat osteoporosis (a ... and possible adverse side effects on oral health, according to ... of the American Dental Association (JADA). , Use of ... bisphosphonate-associated osteonecrosis of the jaw (BON) that occurs spontaneously or ...
... ... at over 3,000 retail sites. , ... (PRWEB) May 26, 2010 -- Buckts Firefox Add-on delivers discounts and ... purchase. When a shopper visits an online retailer, clicking on the highlighted ShoppingBuckt ...
... ... $100,000 per-violation penalties , ... Alexandria, VA (Vocus) May 26, 2010 -- More than ten major retailers, representing ... offered by the National Association of Chain Drug Stores (NACDS) and RollStream. ...
... expected changes to oversight of supplement industry , WEDNESDAY, ... dietary herbal supplements has found trace amounts of lead, ... tested, plus myriad illegal health claims made by supplement ... , The levels of heavy metal contaminants did not ...
Cached Medicine News:Health News:Genentech uses Complete Genomics' human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature 2Health News:Some bisphosphonates users unfamiliar with drug's possible side effects on oral health 2Health News:Retailers and Manufacturers Quickly Adopt Online Network to Address CPSIA Compliance 2Health News:Retailers and Manufacturers Quickly Adopt Online Network to Address CPSIA Compliance 3Health News:Many Supplements Said to Contain Toxins, Make False Health Claims 2
Bausch & Lomb SofLens59 contact lenses combine excellent performance, comfort and visual acuity providing daily wear for two week replacement....
The Prism Exophthalmometer provides precise measurement of patient's exophthalmos....
PLX40s, 40 Watt Sealed CO2 Laser System....
Both corneal topography and refractive error data are measured together in a single step to minimize alignment errors. Objective autorefractometry and autokeratometric readings of sphere, cylinder an...
Medicine Products: